

**Supplementary table 5. Multicentre studies on COVID-19 in patients with haematologic malignancies reported during 2020**

	Kind of Study/Country	AML cases/deaths	MDS cases/deaths	CMD cases/deaths	NHL and HL cases/deaths	MM cases/deaths	ALL cases/deaths	CLL cases/deaths	Others cases/deaths	Total cases/deaths
<b>Passamonti et al. Lancet Hematol 2020</b>	Italy	51/22 (43%)	41/20 (49%)	83/27 (33%)	170/65(38%)	106/39 (37%)	16/3 (19%)	69/22 (32%)	-	536/198 (37%)
<b>Yigenoglu et al. Med Virol 2020</b>	Turkey	40/8 (20%)	146/22 (15%)	146/13 (9%)	250/28 (11%)	77/15 (19.5%)	18/3 (17%)	54/9 (17%)	9/4 (44%)	740/102 (13.8%)
<b>Garcia Suarez et al. Hematol Oncol 2020</b>	Spain	61/27 (44%)	78/33 (42%)	79/14 (18%)	220/68 (31%)	137/47 (34%)	13/2 (15%)	109/39 (36%)	-	697/230 (33%)
<b>Glentoj et al. Eur J Haematol 2020</b>	Denmark	8/5 (63%)	-	-	-	11/2 (18%)	-	31/6 (19%)	16/3 (19%)	66/16 (24%)
<b>Lee et al. Lancet Oncol 2020</b>	UK	79/33 (42%)	-	-	79/25 (32%)	37/16 (43%)	-	-	29/7 (24%)	224/81 (36%)
<b>Pinana et al. Exp Hemat Oncol 2020</b>	Spain	67	22	29	91	81	25	4	19	338/105 (31%)
<b>Kuderer et al. Lancet 2020</b>	Global	13	-	-	81	55	6	-	49	204/24 (11.8%)
<b>Wood et al. Blood Adv 2020</b>	Global	82/26 (32%)	-	24/6 (25%)	79/20 (25%)	40/11 (28%)	-	29/8 (28%)	-	254/71 (28%)
<b>Borah et al. Blood Cell and Mol Dis 2021</b>	India	24/8 (33%)	11/1 (7%)	4/0 (0%)	37/8 (21.6%)	23/5 (21.6%)	31/4 (14%)	-	-	130/26 (20%)
<b>Cattaneo et al. Cancer 2020</b>	Italy	8/4 (50%)	6/4 (67%)	10/5 (50%)	42/17 (41%)	18/5 (28%)	-	11/3 (27%)	7/2 (29%)	102/40 (39%)
<b>ASH research collaborative 2021^</b>	Global registry data summaries	337/57 (16.9%)	-	103/12 (11.6%)	259/48 (18.5%)	207/30 (14.5%)	-	119/20 (16.8%)	-	1013/165 (16.3%)
<b>Totals/deaths</b>										<b>4304/1058 (24.6%)</b>

AML, acute myeloid leukaemia; MDS, myelodysplastic syndrome; CMD, chronic myeloproliferative diseases; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; MM, multiple myeloma; ALL, acute lymphatic leukaemia; CLL, chronic lymphatic leukaemia. ^ Data updated at June 2021.